Fig. 4: RIPK3 is a target of Ibrutinib.
From: Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
a Plasmid expressing HA-mRIPK3 or Vector was transfected into 293T cells. Then the cells were treated with indicated concentrations of Ibrutinib, GSK’872 (10 μM), NEC-1 (20 μM) for 20 h. The cells were harvested and analyzed with indicated antibodies. b Hela-RIPK3 or HT-29 was treated with Ibrutinib (15 μM) for the indicated times. Then the cells were harvested and analyzed with indicated antibodies. c In vitro ADP-Glo kinase assay using recombinant hRIPK3 protein. Recombinant hRIPK3 was incubated with DMSO, GSK’872 (10 μM) or Ibrutinib (10 μM). For DMSO and Ibrutinib, n = 4 biologically independent samples. For GSK’872, n = 5 biologically independent samples. d Molecular Docking simulation result of Ibrutinib and RIPK3 using RIPK3 structure (PDB code: 7MX3)38. e L929 cells were treated with Ibrutinib (15 μM) before or after challenging with TZ. Then cell viabilities were determined using CCK8 method. n = 3 biologically independent samples. f L929 cells were treated with Ibrutinib (15 μM) before or after challenging with TZ. Then cells were harvested and analyzed with indicated antibodies. Data shown are representative of three independent experiments. Means ± SD. #p < 0.01.
